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FPIN's Clinical Inquiries 
Treatments for Chronic Prostatitis 
Clinical Question 
What is the best treatment for chronic nonbacterial prostatitis? 
Evidence-Based Answer 
Because the etiology of chronic nonbacterial prostatitis is unknown, a variety of treatments have 
been proposed. The best-designed, largest clinical trials have not found the most commonly used 
therapies (i.e., alpha blockers, quinolone antibiotics, nonsteroidal anti-inflammatory drugs, 
finasteride [Propecia]) to be effective. [Strength of recommendation: B, randomized controlled 
trials (RCTs)] 
Allopurinol (Zyloprim), phytochemicals, and transurethral thermotherapy have been suggested 
as treatment options, but evidence of their effectiveness is lacking. [Strength of recommendation: 
B, expert opinion or inconclusive trials] 
Evidence Summary 
The National Institutes of Health (NIH) developed a new classification for prostatitis in 1995 
(Table 11). This standardized the inclusion criteria for clinical trials of chronic nonbacterial 
prostatitis and prostadynia.1 It is estimated that patients with nonbacterial prostatitis constitute 
90 percent of all cases of prostatitis.2 Outcome measurement was standardized by the 
development of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI), a validated symptom 
score.3 
Table 1 
NIH Classification of Prostatitis 
Category Symptoms 
I. Acute infection of the prostate gland Acute febrile illness associated with 
perineal and suprapubic pain, dysuria, and 
obstructive voiding symptoms 
II. Chronic infection of the prostate gland Recurrent urinary tract infections with 
pain and voiding disturbances 
III. Chronic genitourinary pain in the Chronic perineal, suprapubic, testicular, 
absence of uropathogenic bacteria 
localized to the prostate gland employing 
standard methodology 
penile, or ejaculatory pain associated with 
variable dysuria and obstruction and 
irritative voiding symptoms 
IIIa. Significant number of white blood 
cells in expressed prostatic secretions, 
postprostatic massage urine sediment, or 
semen 
See category III 
IIIb. Insignificant number of white blood 
cells in expressed prostatic secretions, 
postprostatic massage urine sediment, or 
semen 
See category III 
IV. White blood cells (or bacteria) in 
expressed prostatic secretions, 
postprostatic massage urine sediment, 
semen, or histologic specimens of prostate 
gland 
Asymptomatic  
 
NIH = National Institutes of Health. 
Information from reference 1. 
The Cochrane systematic review of interventions for chronic nonbacterial prostatitis concluded 
that the use of alpha blockers or antibiotics is not supported by the current evidence.4 The 
studies identified had few participants; used inconsistent or nonvalidated outcome measures; and, 
although statistically significant improvements were sometimes seen, their clinical significance 
is uncertain. 
Alpha blockers and quinolone antibiotics were shown to be ineffective by a larger, more recent, 
and better-designed RCT of 196 men with chronic nonbacterial prostatitis.5 These results are 
consistent with a well-designed study6 of 80 men that showed no significant symptomatic 
improvement after six weeks of treatment with levofloxacin (Levaquin). Neither of these more 
recent, higher-quality RCTs5,6 was included in the Cochrane review, but they strengthened the 
recommendation against routinely using alpha blockers or antibiotics for this problem. 
A single RCT with 161 patients found no benefit from Rofecoxib (Vioxx).7 Two studies 
evaluated finasteride.8,9 The earlier of these two studies was flawed because the treatment group 
and control group were different at baseline, making posttreatment comparisons invalid.8 This 
study also did not use a validated symptom score, making it difficult to compare with other 
studies. A more recent and larger RCT9 of finasteride versus placebo showed no difference 
between the two. 
A systematic review10 identified only one small RCT11 of limited quality that evaluated 
allopurinol in 54 patients. It found a small symptomatic benefit; however, the limitations in the 
study design do not allow allopurinol to be routinely recommended for this condition.10 
Similarly, quercetin12 and pentosan [Elmiron]13 are phytochemicals that have been evaluated 
for the treatment of chronic nonbacterial prostatitis, but the studies were small and the results 
inconclusive. 
A variety of transurethral or transrectal heat treatments have been tried, but the studies were 
small and the potential side effects (e.g., hematuria, erectile dysfunction, premature ejaculation, 
urinary retention, urinary tract infection, urinary incontinence) limited the utility of these 
therapies.14 Only one small study with 10 patients15 used a validated outcome measure and 
sham therapy for the control group. Although the authors were encouraged by the possibility of 
an effective treatment, they acknowledged that larger confirmatory trials were necessary. 
Recommendations from Others 
There were no U.S. guidelines for the treatment of chronic prostatitis found in the National 
Guideline Clearinghouse. A 2001 British Association for Sexual Health and HIV guideline16 for 
treating chronic nonbacterial prostatitis stated that "there are no universally effective treatments 
for chronic abacterial prostatitis/chronic pelvic pain syndrome. The lack of knowledge of the 
etiology of these conditions means that no specific recommendations can be made and treatment 
choice is usually trial and error." The American Urological Association has no guideline related 
to prostatitis listed on its Web site. 
Clinical Commentary 
The etiology of chronic nonbacterial prostatitis is unknown. Because there may be multiple 
etiologies, it will be hard for any single therapy to have an effect large enough to demonstrate 
effectiveness in clinical trials. Taking a patient history may provide physicians with clues as to 
where to start, and also decrease patient anxiety about the condition. Encouraging patients to 
notice aggravating and alleviating factors will help them gain a sense of control. Individual 
therapeutic trials of relatively safe drugs such as alpha blockers or allopurinol may be a 
reasonable option, with the patient keeping a symptom diary to evaluate effectiveness. 
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